Pipeline: BPI-7711

EGFR T790M

Mutation positive non-small cell lung cancer

 

Mode of Action

Third generation EGFR TKI for the treatment of advanced NSCLC harboring common EGFR mutation and the EGFR gatekeeper mutation (T790M). Fifty percent of all patients treated with a 1st or 2nd generation EGFR-TKI will develop the T790M gatekeeper mutation and present with disease progression.

Download the Poster

Status

  • Pre-clinical development complete.
  • Chinese clinical trial application (CTA) filed. Approval expected Q3 2016
  • Chinese Clinical trial to start Q4 2016

Click on the image to expand and view description.

Efficacy evaluation of BPI-7711 against H1975 human non-small cell lung carcinoma in female nude mice
Efficacy evaluation of BPI-7711 against HCC827 human non-small cell lung carcinoma in female nude mice